Hormone-dependent prostate cancer

4 trials 1 recruiting MedDRA PT
4 Registered trials
1 Recruiting
4 Unique sponsors
10 Unique IMPs
2 Commercial trials
Drug classes (ATC)
— ATC code not specified 2
V Various (ATC V) 1
L Oncology (ATC L) 1
Mechanism of action (INN-stem analysis)
Unknown / small molecule 8 substances
Radiopharmaceutical 1 substance
Taxane 1 substance
Phase III: 2 Phase II: 2

Filter these 4 trials by country, sponsor, date range and more.

Open in Search → Gap analysis →
Show: 4 trials

Phase III

2 trials
  • Novartis Pharma AG Commercial
    GOZETOTIDE; LUTETIUM (177LU) VIPIVOTIDE TETRAXETAN
    2022-502956-29-00 11 countries 2024 n=215
    Recruiting
  • Friedrich-Schiller-Universitaet Jena Academic
    BUSERELIN ACETATE; DAROLUTAMIDE; DEGARELIX; DOCETAXEL; GOSERELIN ACETATE; LEUPRORELIN ACETATE; RELUGOLIX
    2022-502634-52-00 2 countries 2023 n=280
    Ended

Phase II

2 trials
  • UroTrials GmbH Commercial
    BMS-986365
    2025-523672-23-00 1 country n=42
    Pending
  • European Organisation For Research And Treatment Of Cancer Academic
    DAROLUTAMIDE
    2024-510840-30-00 4 countries 2017 n=169
    Ended
Sponsor activity
SponsorTypeTrialsPhasesRecruiting
UroTrials GmbH Commercial 1 Phase II 0
Novartis Pharma AG Commercial 1 Phase III 1
European Organisation For Research And Treatment Of Cancer Academic 1 Phase II 0
Friedrich-Schiller-Universitaet Jena Academic 1 Phase III 0
New trials by year
2023
1
2024
1
← All indication landscapes